Recently, several studies provided evidences showing that the levels of PD-L1 was significantly increased in the breast and colon cancer cells treated with resveratrol at supra-pharmacological concentrations (> 50 μM) and, in contrast, resveratrol antagonizes thyroid hormone-induced PD-L1 expression in oral cancer cells also at relatively high concentrations (> 40 μM) (Lin et al. 2019; Lucas et al. 2018), indicating that effects of resveratrol on PD-L1 expression could be the dose-, and cell-type dependent. This evidence concerns the gene TG and colonic neoplasm.